Skip to Content
Merck
  • Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses.

Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses.

The EMBO journal (2014-06-27)
Min Peng, Jenny Xie, Anna Ucher, Janet Stavnezer, Sharon B Cantor
ABSTRACT

Several proteins in the BRCA-Fanconi anemia (FA) pathway, such as FANCJ, BRCA1, and FANCD2, interact with mismatch repair (MMR) pathway factors, but the significance of this link remains unknown. Unlike the BRCA-FA pathway, the MMR pathway is not essential for cells to survive toxic DNA interstrand crosslinks (ICLs), although MMR proteins bind ICLs and other DNA structures that form at stalled replication forks. We hypothesized that MMR proteins corrupt ICL repair in cells that lack crosstalk between BRCA-FA and MMR pathways. Here, we show that ICL sensitivity of cells lacking the interaction between FANCJ and the MMR protein MLH1 is suppressed by depletion of the upstream mismatch recognition factor MSH2. MSH2 depletion suppresses an aberrant DNA damage response, restores cell cycle progression, and promotes ICL resistance through a Rad18-dependent mechanism. MSH2 depletion also suppresses ICL sensitivity in cells deficient for BRCA1 or FANCD2, but not FANCA. Rescue by Msh2 loss was confirmed in Fancd2-null primary mouse cells. Thus, we propose that regulation of MSH2-dependent DNA damage response underlies the importance of interactions between BRCA-FA and MMR pathways.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human MSH2
Sigma-Aldrich
MISSION® esiRNA, targeting human RAD18
Sigma-Aldrich
MISSION® esiRNA, targeting human BRCA1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Mlh1
Sigma-Aldrich
MISSION® esiRNA, targeting human MLH1
Sigma-Aldrich
MISSION® esiRNA, targeting human FANCD2
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Fancd2
Sigma-Aldrich
MISSION® esiRNA, targeting human FANCA
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Brca1